Traditional chinese medicine composition for ameliorating functional constipation
The traditional Chinese medicine formula, consisting of senna leaves, magnolia bark, astragalus root, and cistanche, addresses constipation in the elderly population, providing a safe and effective treatment that significantly improves constipation symptoms and reduces side effects.
Patent Information
- Application Number
- PCT/CN2025/093228
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2025-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Existing medications for treating functional constipation in the elderly are not effective and have side effects, necessitating the development of safer and more effective traditional Chinese medicine combinations.
A traditional Chinese medicine composition formula using senna leaves, magnolia bark, astragalus root, and cistanche as the main ingredients, through the synergistic effect of each ingredient, forms concentrated traditional Chinese medicine granules or other preparations, used to improve intestinal function and promote defecation.
It significantly improves constipation symptoms in the elderly, reduces intestinal dependence, increases stool volume and water content, reduces the incidence of side effects, and is suitable for long-term use.
Smart Images

Figure CN2025093228_12112026_PF_FP_ABST
Abstract
Description
Traditional Chinese medicine composition for improving functional constipation Technical Field
[0001] This invention relates to a traditional Chinese medicine prescription aimed at treating functional constipation (FC) in the elderly population. Specifically, the technical field of this invention includes traditional Chinese medicine, geriatrics, and the treatment of digestive system diseases. Background Technology
[0002] Functional constipation (FC) is one of the most common digestive disorders among the elderly. Studies show that the prevalence of FC in Chinese people aged 60 and above is 15% to 20%, significantly higher than in non-elderly populations. The elderly have weaker intestinal function, making them more susceptible to the effects of lifestyle habits, diet, and activity levels, which can exacerbate constipation. For patients with chronic constipation, over 50% are not entirely satisfied with existing treatments, indicating limitations in the effectiveness and safety of current methods. Therefore, developing new, more durable, and safer treatments is a significant practical need for treating functional constipation in the elderly.
[0003] Currently, single-component medications are insufficient for achieving satisfactory results in the treatment of functional constipation, and existing treatments often involve significant side effects. While Western medicine is common, long-term use can lead to intestinal dependence and other adverse reactions, thus patients often seek safer and more effective treatment options. In contrast, traditional Chinese medicine formulas often play a positive role in the treatment of multiple diseases and have a relatively high safety profile with long-term use. To date, neither in China nor internationally, any Chinese herbal medicines have been approved specifically for the treatment of functional constipation in the elderly.
[0004] Therefore, there is a need to develop a new, safer, and more durable therapeutic agent specifically for treating functional constipation in the elderly population. This invention addresses this need. Summary of the Invention
[0005] This invention provides a novel plant-based medicine, a traditional Chinese medicine formula specifically for functional constipation in the elderly. This formula combines clinical experience from traditional prescriptions with modern pharmacological and toxicological research data, and selects senna leaves, magnolia bark, astragalus root, and cistanche deserticola as main ingredients to form a new and effective compound. This provides a solid foundation for the modernization of traditional Chinese medicine and offers a safer and more effective drug option for the treatment of functional constipation in the elderly.
[0006] In a first aspect, the present invention provides a traditional Chinese medicine formulation for improving functional constipation, comprising the following ingredients in weight percentage ranges: senna leaves: 5% to 25%; magnolia bark: 20% to 60%; astragalus: 10% to 45%; and cistanche: 10% to 50%.
[0007] In one embodiment, the traditional Chinese medicine composition formula is one or more of the following: concentrated traditional Chinese medicine granules, extracts, powders, pills, oral liquids, films, patches, or external preparations.
[0008] In one embodiment, the daily dosage of the traditional Chinese medicine composition formula is 0.1-2.0 grams per kilogram of body weight.
[0009] In one embodiment, the traditional Chinese medicine composition formulation further includes one or more excipients selected from dextrin, lactose, microcrystalline cellulose, sucrose, gelatin, hydroxypropyl methylcellulose, crospovidone, talc, or magnesium stearate.
[0010] In a second aspect, the present invention provides a method for preparing a medicament for improving functional constipation, comprising extracting a traditional Chinese medicine composition formulation and mixing it with one or more excipients and pharmaceutically acceptable excipients to prepare a pharmaceutical preparation suitable for the treatment of said functional constipation.
[0011] In one embodiment, the pharmaceutical preparation comprises the following ingredients in weight percentage ranges: senna leaves: 5% to 25%; magnolia bark: 20% to 60%; astragalus: 10% to 45%; and cistanche: 10% to 50%.
[0012] In one embodiment, pharmaceutically acceptable excipients include dextrin and powdered sugar.
[0013] In one embodiment, one or more excipients are selected from dextrin, lactose, microcrystalline cellulose, sucrose, gelatin, hydroxypropyl methylcellulose, crospovidone, talc, or magnesium stearate.
[0014] In one embodiment, the pharmaceutical preparation is a tablet, capsule, solution, granule, or powder.
[0015] In one embodiment, the pharmaceutical preparation is administered orally or by gavage.
[0016] In one embodiment, the daily dosage of the pharmaceutical preparation is 0.1-0.5 grams per kilogram of body weight.
[0017] In one embodiment, the pharmaceutical preparation is used to improve fecal output, shorten intestinal transit time, and increase fecal moisture content.
[0018] In one embodiment, the pharmaceutical preparation can be used to prevent or reduce intestinal dependence caused by long-term use of laxatives.
[0019] In one embodiment, the pharmaceutical preparation further includes a probiotic component selected from Lactobacillus acidophilus, Bifidobacterium, Lactobacillus rhamnosus, or Lactobacillus plantarum.
[0020] In one embodiment, the pharmaceutical preparation may be used in combination with dietary fiber to enhance its effect in improving constipation.
[0021] In one embodiment, the pharmaceutical preparation may be formulated into a dosage form suitable for children, adults, or the elderly.
[0022] In one embodiment, the dosage of the traditional Chinese medicine composition can be adjusted according to the patient's age, weight, and condition, with an application range of 0.28-1.25 grams per kilogram of body weight per day.
[0023] In one embodiment, the daily dosage is 1 to 5 grams for patients with mild constipation and 10 to 50 grams for patients with severe constipation.
[0024] In one embodiment, the pharmaceutical formulation exhibits an effect of reducing loperamide-induced constipation without significant toxic side effects. Attached Figure Description
[0025] Embodiments of the invention are described in more detail below with reference to the accompanying drawings, in which:
[0026] Figure 1 shows a comparison of the effects of two positive control drugs and concentrated traditional Chinese medicine granules formulated with the traditional Chinese medicine composition of this invention on defecation frequency in an aged mouse constipation model 6 hours after induction with loperamide.
[0027] Figure 2 shows a comparison of the effects of two positive control drugs and concentrated traditional Chinese medicine granules of the formulation of the traditional Chinese medicine composition of the present invention on the overall intestinal transit time in an aged mouse constipation model 6 hours after loperamide induction.
[0028] Figure 3 shows a comparison of the effects of two positive control drugs and concentrated traditional Chinese medicine granules of the herbal composition formulation of this invention on the water content in an aged mouse constipation model 6 hours after loperamide induction.
[0029] Figure 4 shows the changes in absorption ratio (g / g) of the hydrogel compositions of Examples 1 to 4 at different time points.
[0030] Figure 5 shows the degradation rate changes of Example 3 and Comparative Example 1 in PBS buffer from 0 to 72 hours.
[0031] Figure 6 shows the surface morphology of the hydrogel sample of Example 3 after 72 hours of PBS immersion, observed by scanning electron microscopy (SEM). Detailed Implementation
[0032] Functional constipation (FC) is the most common gastrointestinal disease among the elderly. Single-component drug treatments are often ineffective, and existing drug formulations frequently lack in-depth research on the interaction mechanisms of their components. Therefore, the traditional Chinese medicine composition of this invention utilizes the synergistic effects of senna leaves, magnolia bark, astragalus root, and cistanche to overcome the shortcomings of existing formulations and provide a novel treatment option.
[0033] Specifically, this invention provides a traditional Chinese medicine formula comprising the four main ingredients listed in Table 1: senna leaf, magnolia bark, astragalus root, and cistanche, in the following weight ratios: 5% to 25% senna leaf, 20% to 60% magnolia bark, 10% to 45% astragalus root, and 10% to 50% cistanche root. Senna leaf directly stimulates intestinal peristalsis, thus relieving constipation. Magnolia bark helps regulate the flow of qi in the intestines, resolving constipation caused by qi stagnation. Astragalus root enhances blood circulation, improves intestinal motility, and promotes defecation. Cistanche root moistens the intestines, relieves constipation, tonifies the kidneys and replenishes essence, regulates intestinal moisture and kidney qi, and helps prevent recurrence of constipation.
[0034] Table 1
[0035] Senna leaf, magnolia bark, astragalus root, and cistanche are the main ingredients of this invention, and they synergistically improve functional constipation through their unique effects. Senna leaf stimulates intestinal smooth muscle, promotes peristalsis, and quickly relieves constipation; magnolia bark promotes qi circulation, relieves qi stagnation, and alleviates abdominal distension and constipation caused by qi stagnation; astragalus root strengthens qi and blood circulation, improves intestinal motility, and prevents constipation recurrence; cistanche moistens the intestines, promotes bowel movements, tonifies the kidneys and replenishes essence, enhances physical strength, and improves intestinal function. The four ingredients work together in a coordinated manner to regulate the stomach and intestines, relieve constipation, enhance immunity, and improve qi and blood circulation.
[0036] In another embodiment, the traditional Chinese medicine composition formulation of the present invention can be composed of concentrated Chinese medicine granules (CCMG) containing equivalent raw materials. Compared with traditional Chinese medicine preparations, concentrated Chinese medicine granules not only retain the effective components of Chinese medicine, but also have higher bioavailability and a more convenient method of administration. Furthermore, CCMG, while improving efficacy, has better stability and a longer shelf life, effectively reducing component loss during the preparation process and enhancing the patient's medication experience and treatment effect.
[0037] In addition to concentrated Chinese herbal granules, the most suitable formulation can be selected according to different patient groups and treatment needs. The Chinese herbal composition formulation of this invention can also be prepared into extracts / concentrates, powders, pills, oral liquids, films, patches, or external preparations.
[0038] In another aspect, the present invention provides a method for improving functional constipation, comprising administering to an individual in need an effective amount of a traditional Chinese medicine formulation comprising, by weight, 5% to 25% senna leaves, 20% to 60% magnolia bark, 10% to 45% astragalus root, and 10% to 50% cistanche.
[0039] Based on clinical experience, the recommended dosage range for each ingredient is as follows: Senna leaf 1-10 g, Magnolia officinalis 10-20 g, Astragalus membranaceus 3-30 g, Cistanche deserticola 3-30 g. In animal experiments, a dose equivalent to four times the human clinical dose was used and converted to a dose suitable for mice.
[0040] In one embodiment, the traditional Chinese medicine composition of the present invention is administered orally or by gavage to ensure that the medicinal components are effectively absorbed and exert their therapeutic effect. This administration method allows for better control of the drug dosage and release rate, thereby improving the therapeutic effect.
[0041] Depending on the specific treatment needs, drug characteristics, and patient condition, the most suitable method of administration can be selected to ensure optimal therapeutic effects. For example, for cases requiring rapid onset of action, intravenous (IV) injection allows the herbal solution to directly enter the bloodstream and quickly exert its therapeutic effect. Intramuscular (IM) and subcutaneous (SC) injections are suitable for herbal formulas requiring rapid absorption or long-term sustained release, effectively entering the systemic circulation. Topical administration, such as ointments, patches, or sprays, is suitable for treating local symptoms, especially showing significant efficacy in skin diseases and joint pain. In addition, inhalation and enema administration are also options; the former treats respiratory diseases through the respiratory tract, while the latter allows direct absorption of the drug through the intestines, suitable for digestive system diseases or symptoms such as constipation.
[0042] In one embodiment, the traditional Chinese medicine composition of the present invention has a significant therapeutic effect on functional constipation in the elderly. In an early single-arm clinical trial in Hong Kong (NCT06534996, REC / 23-24 / 0482), the traditional Chinese medicine composition of the present invention demonstrated an 80% complete spontaneous bowel movement (CSBM) response rate, with significant therapeutic effects after two weeks of treatment. During the follow-up period, the traditional Chinese medicine composition of the present invention consistently showed a high CSBM response rate of 60% at different doses, significantly higher than the 20.6% with senna leaf treatment and the 16.5% with placebo treatment. Furthermore, 14% of participants in the study reported at least one adverse event, including abdominal pain and cough, but no serious adverse events occurred. These clinical data indicate that the traditional Chinese medicine composition of the present invention has a low incidence of side effects and high patient compliance, demonstrating its excellent safety and tolerability, and is particularly suitable for long-term use.
[0043] Example:
[0044] The examples and embodiments described herein are for illustrative purposes only, and any modifications or alterations made by those skilled in the art based thereon are included within the spirit and scope of this application. Furthermore, any element or limitation of any invention or embodiment disclosed herein may be combined with any and / or all other elements or limitations disclosed herein (alone or in any combination) or any other invention or embodiment thereof, and all such combinations are considered to be within the scope of this invention and are not subject to such limitations.
[0045] Example 1
[0046] Materials and Methods
[0047] The four herbal granules (senna leaf, magnolia bark, astragalus root, and cistanche) are in different combinations, including low, medium, high concentrations, and the original combination. Loperamide, linaclotide, and hemp seed pills (MZRW) are all commercially available standard medications.
[0048] The experiment used 18-month-old male C57BL / 6J mice, which exhibited good experimental adaptability and stability, making them suitable for evaluating drug efficacy. Mice were randomly divided into 8 groups (n=8 per group): control group, loperamide group (Lop), Lop + linaclotide group, Lop + MZRW group, Lop + low-dose combination group, Lop + medium-dose combination group, Lop + high-dose combination group, and Lop + original dose group.
[0049] The combination of one or more of the above drugs is stored in a desiccator at room temperature. It is administered orally or by gavage to mice.
[0050] On the day of the experiment, mice were given 0.2 ml of activated charcoal mixed diet (charcoal meal). The time of gavage was recorded as T1. The mice were then placed alone in cages and allowed free access to food and water. The time when the first black fecal particles appeared was recorded as T2. The intestinal transit time (T) was calculated as: T = T2 - T1, which represents the time required from gavage to fecal excretion.
[0051] The number of fecal particles in mice within 6 hours after drug administration was recorded as fecal frequency. Fecal samples were placed in 2 mL centrifuge tubes of known weight, and the wet weight of the feces was recorded. After drying the fecal samples overnight at 105°C, their dry weight was recorded, and the fecal moisture content was calculated to compare the fecal moisture content of each group.
[0052] Statistical analysis was performed using GraphPad 10 software, and results are expressed as mean ± standard deviation (SEM). One-way ANOVA was used to analyze differences between groups in fecal frequency, fecal moisture content, and overall intestinal transit. A p-value < 0.05 was considered statistically significant.
[0053] Example 2
[0054] The anti-constipation effect of the traditional Chinese medicine composition on a loperamide-induced mouse constipation model
[0055] This study aims to evaluate the therapeutic effect of a traditional Chinese medicine (TCM) composition on loperamide-induced functional constipation in mice. Loperamide, a commonly used antidiarrheal drug, often causes constipation as a side effect. This study uses this model to evaluate the anti-constipation effect of the TCM composition.
[0056] The raw materials and dosages of each component in the traditional Chinese medicine composition are listed in Table 2:
[0057] Table 2
[0058] On the day of the experiment, male C57BL / 6J mice were randomly assigned to groups as described in Example 1 and administered different drugs. Referring to Table 3, firstly, functional constipation was induced in mice in each experimental group using 0.5 mg / ml loperamide for approximately 6 hours. The gavage volume was 5 ml / kg, while the control group was administered 5 ml / kg Mili-Q water. Subsequently, the control group and Lop group were administered 5 ml / kg Mili-Q water, the Lop + linaclotide group was administered 5 ml / kg linaclotide, the Lop + MZRW group was administered 10 ml / kg hemp seed pill solution, the Lop + low-dose combination group was administered 10 ml / kg low-dose traditional Chinese medicine composition, the Lop + medium-dose combination group was administered 10 ml / kg medium-dose traditional Chinese medicine composition, the Lop + high-dose combination group was administered 10 ml / kg high-dose traditional Chinese medicine composition, and the Lop + original dose group was administered 10 ml / kg original traditional Chinese medicine composition.
[0059] Table 3
[0060] All treatment groups using traditional Chinese medicine formulas were administered CCMG via gavage. Referring to Figure 1, the number of fecal particles excreted by mice within 6 hours after gavage administration of the drugs in each group was shown. The normal control group had normal fecal excretion with a relatively high number of particles; the loperamide group showed a significant decrease (P<0.0001), indicating that loperamide successfully induced constipation; the loperamide + linaclotide group showed a significant increase in fecal excretion compared to the loperamide group (P=0.0381); the loperamide + MZRW group showed a significant improvement in fecal excretion (P=0.0034); the loperamide + low-dose group showed some improvement compared to the loperamide group (P=0.0443); the loperamide + medium-dose group showed a further increase in fecal excretion (P=0.0001); the loperamide + high-dose group showed a significant increase in fecal excretion (P=0.0002); the loperamide + original dose group performed well, similar to the high-dose group (P=0.0359). The results confirmed that linaclotide, hemp seed pills, and different doses of traditional Chinese medicine combinations could all relieve loperamide-induced constipation to varying degrees. The medium and high dose groups showed more significant effects, comparable to the hemp seed pill group.
[0061] Referring to Figure 2, the overall intestinal transit time changed significantly after loperamide induction, and the combination of different doses of the traditional Chinese medicine composition with the two positive control drugs significantly improved the overall intestinal transit time.
[0062] The above experimental results confirm that the traditional Chinese medicine composition provided by the present invention has a significant effect on treating constipation and can be further developed as a potential constipation treatment drug.
[0063] Example 3
[0064] Comparison of the effects of traditional Chinese medicine composition formulations on fecal moisture content in a loperamide-induced mouse fecal model
[0065] Referring to Figure 3, mice treated with loperamide did not show significant changes in fecal moisture content, but compared with the control group and the loperamide-treated group, the combination of high concentration and original dose of traditional Chinese medicine granules significantly increased fecal moisture content.
[0066] Example 4
[0067] Referring to Table 4, firstly, functional constipation was induced in mice of each experimental group using 0.5 mg / ml loperamide for approximately 6 hours. The gavage volume was 5 ml / kg, while the control group was given 5 ml / kg Mili-Q water. Subsequently, the control group and Lop group were given 5 ml / kg Mili-Q water, the Lop + linaclotide group was given 5 ml / kg linaclotide, the Lop + MZRW group was given 10 ml / kg hemp seed pill solution, the Lop + low-dose combination group was given 10 ml / kg low-dose traditional Chinese medicine composition, the Lop + medium-dose combination group was given 10 ml / kg medium-dose traditional Chinese medicine composition, the Lop + high-dose combination group was given 10 ml / kg high-dose traditional Chinese medicine composition, and the Lop + original dose group was given 10 ml / kg original traditional Chinese medicine composition.
[0068] In this example, a charcoal solution with a concentration of 0.1 g / ml (5 ml / kg) was used as an indicator to monitor the whole intestinal transit time in mice.
[0069] Table 4
[0070] Example 5
[0071] Materials and Methods
[0072] The product contains concentrated granules of four herbs (senna leaf, magnolia bark, astragalus root, and cistanche), in different combinations, including low, medium, high concentrations, and the original combination. Linaclotide and Ma Zi Ren Wan (MZRW) are both commercially available standard medications.
[0073] The experiment used 24-month-old and 6-week-old male C57BL / 6J mice, which exhibited good experimental adaptability and stability, making them suitable for evaluating drug efficacy. The mice were divided into 8 groups (n=10 per group): 6-week group, 24-month group (Lop), 24-month + linaclotide group, 24-month + MZRW group, 24-month + low-dose combination group, 24-month + medium-dose combination group, 24-month + high-dose combination group, and 24-month + original dose group.
[0074] The combination of one or more of the above drugs is stored in a desiccator at room temperature. It is administered to mice by gavage.
[0075] On the day of the experiment, mice were given 0.2 ml of activated charcoal mixed diet (charcoal meal). The time of gavage was recorded as T1. The mice were then placed alone in cages and allowed free access to food and water. The time when the first black fecal particles appeared was recorded as T2. The intestinal transit time (T) was calculated as: T = T2 - T1, which represents the time required from gavage to fecal excretion.
[0076] The number of fecal particles in mice within 6 hours after drug administration was recorded as fecal frequency. Fecal samples were placed in 2 mL centrifuge tubes of known weight, and the wet weight of the feces was recorded. After drying the fecal samples overnight at 105°C, their dry weight was recorded, and the fecal moisture content was calculated to compare the fecal moisture content of each group.
[0077] Statistical analysis was performed using GraphPad 10 software, and results are expressed as mean ± standard deviation (SEM). One-way ANOVA was used to analyze differences between groups in fecal frequency, fecal moisture content, and overall intestinal transit. A p-value < 0.05 was considered statistically significant.
[0078] Example 6
[0079] The effect of a traditional Chinese medicine composition on promoting defecation in 24-month-old mice
[0080] This study aims to evaluate the effect of a traditional Chinese medicine (TCM) composition on defecation in 24-month-old mice. The anti-constipation effect of the TCM composition was assessed by comparing young and aged mice, and by comparing the defecation of aged mice after administration with that of unadministered aged mice.
[0081] The raw materials and dosages of each component in the traditional Chinese medicine composition are listed in Table 2:
[0082] Table 5
[0083] On the day of the experiment, male C57BL / 6J mice were randomly assigned to groups as described in Example 6 and administered different drug treatments. Referring to Table 6, the 6-week and 24-month groups were administered 5 ml / kg of Mili-Q water by gavage. Subsequently, the 24-month + linaclotide group was administered 10 ml / kg of linaclotide by gavage, the 24-month + MZRW group was administered 10 ml / kg of hemp seed pill solution by gavage, the 24-month + low-dose combination group was administered 10 ml / kg of a low-dose traditional Chinese medicine composition, the 24-month + medium-dose combination group was administered 10 ml / kg of a medium-dose traditional Chinese medicine composition, the 24-month + high-dose combination group was administered 10 ml / kg of a high-dose traditional Chinese medicine composition, and the 24-month + original dose group was administered 10 ml / kg of the original traditional Chinese medicine composition.
[0084] Table 6
[0085] All treatment groups using the traditional Chinese medicine (TCM) combination formulas were administered CCMG via gavage. Referring to Figure 4, the number of fecal particles excreted by mice within 6 hours after gavage showed a significant increase in fecal volume in the 6-week group compared to the 24-month group (P = 0.0017); the 24-month group plus linaclotide showed a significant increase in fecal volume compared to the 24-month group (P = 0.0404); the 24-month group plus the original dosage showed good results, similar to the linaclotide group (P = 0.0404); the 24-month group plus the high-dose group showed a further increase in fecal volume (P < 0.0001). These results confirm that linaclotide and different dosages of the TCM combination can increase the defecation frequency of aged mice to varying degrees, with the high-dose group showing the most significant effect.
[0086] The above experimental results confirm that the traditional Chinese medicine composition provided by the present invention has a significant effect on treating constipation and can be further developed as a potential constipation treatment drug.
[0087] Example 7
[0088] Comparison of the effects of traditional Chinese medicine composition formulations on fecal moisture content in 24-month-old mice
[0089] Referring to Figure 5, the fecal water content of mice in the 6-week group was significantly increased compared to the 24-month group (P = 0.0046), and the fecal water content of the 24-month group plus medium dose group was significantly increased compared to the 24-month group (P = 0.0006); the fecal water content of the 24-month group plus high dose group was further increased (P < 0.0001). The results confirm that both medium and high doses of the traditional Chinese medicine combination can increase the fecal water content of aged mice to varying degrees, with the high dose group showing a more significant effect.
[0090] Example 8
[0091] Referring to Table 7, the 6-week and 24-month groups were administered 5 ml / kg of Mili-Q water by gavage, with a gavage volume of 5 ml / kg. Subsequently, the 24-month + linaclotide group was administered 10 ml / kg of linaclotide by gavage, the 24-month + MZRW group was administered 10 ml / kg of hemp seed pill solution by gavage, the 24-month + low-dose combination group was administered 10 ml / kg of low-dose traditional Chinese medicine composition by gavage, the 24-month + medium-dose combination group was administered 10 ml / kg of medium-dose traditional Chinese medicine composition by gavage, the 24-month + high-dose combination group was administered 10 ml / kg of high-dose traditional Chinese medicine composition by gavage, and the 24-month + original dose group was administered 10 ml / kg of original traditional Chinese medicine composition by gavage.
[0092] In this example, a charcoal solution with a concentration of 0.1 g / ml (5 ml / kg) was used as an indicator to monitor the whole intestinal transit time in mice.
[0093] Table 7
[0094] Referring to Figure 6, compared with normal 6-week-old young mice, the overall intestinal transit time of 24-month-old aged mice changed significantly, and the combination of the original prescription and the high-dose traditional Chinese medicine composition with the two positive drugs improved the overall intestinal transit time.
[0095] The conclusion of this invention indicates that the traditional Chinese medicine composition containing senna leaves, magnolia bark, astragalus root, and cistanche (CCMG) has good potential for the treatment of functional constipation in the elderly and lays a solid foundation for further clinical development.
[0096] definition
[0097] Throughout this specification, unless the context otherwise requires, the word “comprise” or variations such as “comprises” or “comprising” should be understood to imply inclusion of the stated whole or group of wholes, but not to exclude any other whole or group of wholes. It should also be noted that in this disclosure and particularly in the claims and / or paragraphs, terms such as “comprises,” “comprised,” and “comprising” may have the meaning attributed to them under U.S. patent law, for example, allowing elements not expressly listed but excluding elements found in the prior art or elements affecting the essential or novel characteristics of the invention.
[0098] Furthermore, throughout this specification and claims, unless the context otherwise requires, the word "include" or variations thereof, such as "includes" or "including," shall be understood to imply inclusion of the stated whole or group of wholes, but not to exclude any other whole or group of wholes.
[0099] As used herein and unless otherwise defined, the terms “substantially,” “basically,” “approximately,” and “about” are used to describe and explain small variations. When used in conjunction with an event or situation, the terms may cover instances where the event or situation occurred precisely or instances where the event or situation was close to occurring. For example, when used in conjunction with a numerical value, the terms may cover a range of variations less than or equal to ±10% of the numerical value, such as less than or equal to ±5%, less than or equal to ±4%, less than or equal to ±3%, less than or equal to ±2%, less than or equal to ±1%, less than or equal to ±0.5%, less than or equal to ±0.1%, or less than or equal to ±0.05%.
[0100] References to "an embodiment," "an example embodiment," "exemplary embodiment," etc., in this specification indicate that the described embodiment may include specific features, structures, or characteristics, but not every embodiment necessarily includes specific features, structures, or characteristics. Furthermore, such phrases do not necessarily refer to the same embodiment. Moreover, when a specific feature, structure, or characteristic is described in connection with an embodiment, whether explicitly described or not, it is assumed that the influence of such feature, structure, or characteristic on other embodiments is within the knowledge of those skilled in the art.
[0101] In this article, the term "functional constipation" refers to chronic difficulty in defecation without organic lesions, which is usually manifested as reduced defecation frequency, hard stools, straining during defecation or a feeling of incomplete emptying, and can be diagnosed according to the Rome IV criteria.
[0102] In this article, the term "pharmaceuticalally acceptable excipient" refers to an inert component used in the preparation of a pharmaceutical formulation that can improve the stability, flowability, or mouthfeel of the drug without affecting its primary therapeutic effect.
[0103] Other definitions of the selected terms used herein can be found in the detailed description of the invention and apply throughout. Unless otherwise defined, all other technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
Claims
1. A traditional Chinese medicine formula for improving functional constipation, characterized in that, It contains the following ingredients in weight percentage ranges: Senna leaf: 5% to 25%; Magnolia officinalis: 20% to 60%; Astragalus membranaceus: 10% to 45%; Cistanche deserticola: 10% to 50%.
2. The traditional Chinese medicine composition formula according to claim 1, wherein the traditional Chinese medicine composition formula is one or more of concentrated traditional Chinese medicine granules, extracts, powders, pills, oral liquids, films, patches, or external preparations.
3. The traditional Chinese medicine composition formula according to claim 2, wherein the daily dosage of the traditional Chinese medicine composition formula is 0.1-2.0 grams per kilogram of body weight.
4. The traditional Chinese medicine composition formula according to claim 1, wherein the traditional Chinese medicine composition formula further includes one or more excipients, wherein the one or more excipients are selected from dextrin, lactose, microcrystalline cellulose, sucrose, gelatin, hydroxypropyl methylcellulose, crospovidone, talc or magnesium stearate.
5. A method for preparing a medicament for improving functional constipation, characterized in that, This includes extracting traditional Chinese medicine components and mixing them with one or more excipients and pharmaceutically acceptable excipients to prepare a pharmaceutical formulation suitable for the treatment of said functional constipation.
6. The method of claim 5, wherein the pharmaceutical preparation comprises the following components in the following weight percentage range: senna leaves: 5% to 25%; magnolia bark: 20% to 60%; astragalus: 10% to 45%; cistanche: 10% to 50%.
7. The method of claim 5, wherein the pharmaceutically acceptable excipient comprises dextrin or powdered sugar.
8. The method according to claim 5, wherein one or more excipients are selected from dextrin, lactose, microcrystalline cellulose, sucrose, gelatin, hydroxypropyl methylcellulose, crospovidone, talc, or magnesium stearate.
9. The method according to claim 5, wherein the pharmaceutical preparation is a tablet, capsule, solution, granule or powder.
10. The method of claim 5, wherein the pharmaceutical preparation is administered orally or by gavage.
11. The method according to claim 9 or 10, wherein the daily dosage of the pharmaceutical preparation is 0.1-0.5 grams per kilogram of body weight.
12. The method according to claim 5, wherein the pharmaceutical preparation is used to improve fecal output, shorten intestinal transit time and increase fecal moisture content.
13. The method of claim 5, wherein the pharmaceutical preparation can be used to prevent or reduce intestinal dependence caused by long-term use of laxatives.
14. The method of claim 5, wherein the pharmaceutical preparation further comprises a probiotic component selected from Lactobacillus acidophilus, Bifidobacterium, Lactobacillus rhamnosus, or Lactobacillus plantarum.
15. The method of claim 5, wherein the pharmaceutical preparation may be used in combination with dietary fiber to enhance the effect of improving constipation.
16. The method of claim 5, wherein the pharmaceutical preparation can be formulated into a dosage form suitable for children, adults or the elderly.
17. The method according to claim 5, wherein the dosage of the traditional Chinese medicine composition can be adjusted according to the patient's age, weight and condition, and the application range is 0.28-1.25 grams per kilogram of body weight per day.
18. The method according to claim 5, wherein for patients with mild constipation, the daily dosage is 1 to 5 grams, and for patients with severe constipation, the daily dosage is 10 to 50 grams.
19. The method of claim 5, wherein the pharmaceutical preparation exhibits an effect of reducing loperamide-induced constipation and has no significant toxic side effects.
